Seattle Genetics is a biotechnology company that is based out of Bothell, Washington. The company is centered on providing therapies for the treatment of cancer. The company is well known for being a leader in antibody drug conjugates, which is designed to help target and kill cancer cells while not affecting non targeted cells. Antibody-drug conjugates have been known to reduce the negative effects that traditional forms of chemotherapy may cause in cancer patients. Seattle Genetics is also known for Adcetris, which is also known as Brentuximab Vedotin, a therapy that is now available in over 60 different countries across the globe. Seattle Genetics routinely conducts clinical studies to ensure the therapeutic potential and effectiveness of Brentuximab Vedotin and other cancer fighting tools. Seattle Genetics currently collaborates with Takeda Pharmaceutical Company for the production of Brentuximab Vedotin. Some of the other medicines and technologies produced by Seattle Genetics include ADC targeting CD33, ADC targeting LIV-1, and SGN-CD33A.
Clay B. Siegall, PhD, the Chairman, President and current Chief Executive Officer of Seattle Genetics, co-founded the company in 1998. Siegall attended the University of Maryland where he earned a Bachelors of Science degree in Zoology. He also attended George Washington University where he earned a Ph.D. in Genetics. Before founding Seattle Genetics Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Siegall went on to establish Seattle Genetics with the purpose of producing targeted cancer therapies. In 2011 Siegall reached a milestone in Seattle Genetics’ history by securing FDA approval for Brentuximab Vedotin. Due to his passion and hard work in providing therapeutic cancer treatments, Siegall has been the recipient of many notable awards.